- ►duanessolution.com CG Kiss, C Simader, S Michels, U Schmidt- … - British Journal of Ophthalmology, 2008 - bjo.bmj.com Results: Over 9 months, seven patients gained three to 24 letters and one had
unchanged VA. Three patients lost eight to 24 letters due to recurrence and
received another verteporfin treatment at month 6. Median retinal ... Cited by 4 - Related articles - All 6 versions
[CITATION] PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in …
- ►duanessolution.com S Sacu, A Varga, S Michels, G Weigert, K … - British Medical Journal, 2008 - bjo.bmj.com Results: Baseline characteristics were well balanced in both groups (p>0.05). At
week 12, patients in group A had a mean loss of −3.7 letters compared with a
gain of 3.4 letters in group B (p = 0.04, between both groups). Both ... Cited by 5 - Related articles - All 5 versions
FB Aggio, GB Melo, AL Höfling-Lima, FM Eid - Acta Ophthalmologica Scandinavica, 2006 - ncbi.nlm.nih.gov 1: Acta Ophthalmol Scand. 2006 Dec;84(6):831-3. Photodynamic therapy with
verteporfin combined with intravitreal injection of bevacizumab ... Cited by 9 - Related articles - BL Direct - All 3 versions
AN Antoszyk, L Tuomi, CY Chung, A Singh - American Journal of Ophthalmology, 2008 - Elsevier At month 24, 88% of ranibizumab + PDT patients had lost <15 letters from
baseline VA (vs 75% for PDT alone), 25% had gained ≥15 letters (vs 7% for PDT
alone), and the two treatment arms differed by 12.4 letters in mean VA ... Cited by 15 - Related articles - All 7 versions
MS Ladewig, SE Karl, V Hamelmann, HM Helb, … - Graefe's Archive for Clinical and Experimental …, 2008 - Springer Abstract Background Our aim was to evaluate the short-term safety and efficacy
of combined photodynamic therapy (PDT) with verteporfin and intravitreal
bevacizumab in neovascu- lar age-related macular degeneration (AMD). ... Cited by 15 - Related articles - BL Direct - All 2 versions
CG Kiss, W Geitzenauer, C Simader, G Gregori … - Investigative Ophthalmology & Visual Science, 2009 - ARVO RESULTS. BCVA increased from a mean 60.1 ± 8.7 letters at baseline to 67.0 ±
10.9 at month 3 (P = 0.0003). The CRS at the 0° position increased from 2.8 ±
3.1 dB at baseline to 4.0 ± 5.7 at week 1, remaining stable until month 3. ... Cited by 3 - Related articles - All 3 versions
MEJ van Velthoven, MD de Smet, RO … - Graefe's Archive for Clinical and Experimental …, 2006 - Springer Page 1. Graefe's Arch Clin Exp Ophthalmol (2006) 244: 1119–1123 CLINICAL
INVESTIGATION DOI 10.1007/s00417-005-0209-y MEJ van Velthoven ... Cited by 17 - Related articles - BL Direct - All 4 versions
MJ Potter, CC Claudio, SM Szabo - British Medical Journal, 2009 - bjo.bmj.com Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ... Cited by 1 - Related articles - All 3 versions
NJ Mehta - inperc.com Page 1. Introduction Spectral-Domain (SD) OCT technology, with its superior data
density and speed, has the ability to better differentiate ... Related articles - View as HTML
